Hinge Health, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

HNGE$122.19+5.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and par value data)

March 31,2026 · December 31,2025
Assets
Current assets:
Cash and cash equivalents	$186,671		$207,995
Short-term marketable securities	129,196		155,867
Accounts receivable, net of allowance for credit losses of $5,957 and $6,092 as of March 31, 2026 and December 31, 2025, respectively	114,921		66,061
Deferred commissions	34,507		31,344
Inventory	14,167		15,636
Prepaid expenses and other current assets	60,592		57,001
Total current assets	540,054		533,904
Long-term marketable securities	89,769		113,172
Goodwill	64,096		64,096
Intangible assets, net	2,287		2,512
Property, equipment and software, net	11,350		10,490
Operating lease right-of-use assets	5,956		6,861
Other assets	15,259		13,726
Total assets	$728,771		$744,761
Liabilities, redeemable convertible preferred stock and stockholders’ equity
Current liabilities:
Accounts payable and accrued liabilities	$69,476		$57,331
Operating lease liabilities	4,234		4,223
Deferred revenue	340,766		300,855
Total current liabilities	414,476		362,409
Operating lease liabilities, noncurrent	2,735		3,816
Total liabilities	417,211		366,225
Commitments and contingencies (Note 6)
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, $0.00001 par value; 4,330,341 shares of Series E authorized as of March 31, 2026 and December 31, 2025; 2,581,837 shares of Series E preferred stock issued and outstanding as of March 31, 2026 and December 31, 2025; aggregate liquidation preference of $200,000 as of March 31, 2026 and December 31, 2025	199,874		199,874
Stockholders’ equity:
Class A common stock, $0.00001 par value: 1,000,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 54,523,780 shares and 55,883,690 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	—		—
Class B common stock, $0.00001 par value: 120,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 22,780,358 shares and 23,287,614 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	—		—
Additional paid-in capital	1,127,902		1,229,678
Accumulated other comprehensive loss	(348)	(20)
Accumulated deficit	(1,015,868)		(1,050,996)
Total stockholders’ equity	111,686		178,662
Total liabilities, redeemable convertible preferred stock and stockholders’ equity	$728,771		$744,761

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.